Second malignancies after permanent implant prostate cancer brachytherapy: A single-institution study of 675 patients treated between 1999 and 2003. En savoir plus sur Second malignancies after permanent implant prostate cancer brachytherapy: A single-institution study of 675 patients treated between 1999 and 2003.
[The dawn of radiotherapy, between strokes of genius, dramas and controversies]. En savoir plus sur [The dawn of radiotherapy, between strokes of genius, dramas and controversies].
Long-term results of permanent implant prostate cancer brachytherapy: A single-institution study of 675 patients treated between 1999 and 2003. En savoir plus sur Long-term results of permanent implant prostate cancer brachytherapy: A single-institution study of 675 patients treated between 1999 and 2003.
First-in-human phase I study of the DNA-repair inhibitor DT01 in combination with radiotherapy in patients with skin metastases from melanoma. En savoir plus sur First-in-human phase I study of the DNA-repair inhibitor DT01 in combination with radiotherapy in patients with skin metastases from melanoma.
Risk of second cancers in the era of modern radiation therapy: does the risk/benefit analysis overcome theoretical models? En savoir plus sur Risk of second cancers in the era of modern radiation therapy: does the risk/benefit analysis overcome theoretical models?
Radiological protection in ion beam radiotherapy: practical guidance for clinical use of new technology. En savoir plus sur Radiological protection in ion beam radiotherapy: practical guidance for clinical use of new technology.
Inferring postimplant dose distribution of salvage permanent prostate implant (PPI) after primary PPI on CT images. En savoir plus sur Inferring postimplant dose distribution of salvage permanent prostate implant (PPI) after primary PPI on CT images.
[Which alpha/beta ratio for prostate cancer in 2019?] En savoir plus sur [Which alpha/beta ratio for prostate cancer in 2019?]
[Reirradiations: Which decision-making criteria?] En savoir plus sur [Reirradiations: Which decision-making criteria?]